MEDI0680 - AstraZeneca
AstraZeneca: Annual Report 2015 (AstraZeneca) - Mar 26, 2016 - Discontinuation of MEDI-551 + MEDI0680 in diffuse large B-cell lymphoma due to safety/efficacy reason 
Discontinued • Diffuse Large B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology
http://www.astrazeneca-annualreports.com/2015/assets/pdf/AZ_Annual_Report_2015.pdf
 
Mar 26, 2016
 
.